Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence

Inclusion Criteria: * Kidney recipients aged 18 years and older. * Kidney recipients were transplanted from living or deceased donors * Patients receiving Envarsus® \[Life-Cycle Pharma Tacrolimus\] within 24 hours of kidney transplantation in a once-daily formulation at the discretion of the investiga-tor and in compliance with the summary of product characteristics. * Patients are willing to participate in the study and do not oppose the use of their data. * Patients are either affiliated with or beneficiaries of a social security scheme. Exclusion Criteria: * Contraindications to the use of Life-Cycle Pharma Tacrolimus (Envarsus®). * Pre-transplant desensitization. * ABO is incompatible with a living donor. * Combined transplant (e.g. kidney-heart transplant, kidney-liver transplant). * Previous bariatric (or bypass) surgery. * Gastrointestinal problems are likely to affect the absorption of the Life-Cycle Pharma Tacrolimus (Envarsus®). * Diagnosis of Parkinson's disease or any other neurological syndrome causing tremor. * Patients who are part of another clinical trial or in a period of exclusion from another clinical trial with a molecule under study. * Pregnant women or breastfeeding. * Patients under legal protection (guardianship, curatorship) or deprived of their liberty through judicial or administrative decisions. * Patients under State Medical Assistance.